Меню
Идёт набор NCT06163131

The Effect of Treatment of Emphysema With Endobronchial Valves on the Diaphragm Mobility

Наблюдательное Chronic Obstructive Pulmonary Disease Emphysema or COPD

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально
Состояния в реестре: Chronic Obstructive Pulmonary Disease, Emphysema or COPD. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Дания
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Обзор

In some patients with chronic obstructive pulmonary disease (COPD) the breathlessness is caused by hyperinflation of the lungs. This causes difficulty breathing air out and makes it harder to breath in new air and limits the movement of the diaphram. The diaphragm is the muscle used for breathing between the chest and the stomach. Some of these patients can receive treatment with endobronchial valves, where one-ways are inserted into the bronchial system the let out some of the excess air, and thereby relieve breathlessness. The goal of this observational study is to investigate the effect of endobronchial valves on the mobility of the diaphragm in patients with chronic obstructive pulmonary disease. The main questions it aims to answer are: * If the movement of the diaphragm improves after treatment with endobronchial valves. * If there is a link between improvement of diaphragm function and improvement of symptoms, lung function and physical ability. * If ultrasound scan immediately after the treatment will predict which patients will benefit from the treatment. Participants will undergo ultrasound before, 1 day after and 90 days after the procedure, and lung function examinations from their already planned control visits will be collected.

Подробное описание

When emphysema is present in COPD-patients, the impaired expiratory ventilation causes lung hyperinflation. This results in a change in the respiratory mechanisms of the thorax and thereby impairment of the movement capacity of the muscles. The most important respiratory muscle, the diaphragm, is caudally displaced and flattened, hence, the capacity and mobility of the muscle decreases.

Some patients with COPD fulfill the criteria for treatment with endobronchial valves (EBV) where one-way valves can be inserted in the bronchial system. The mechanism behind the effect of EBV is believed to be formation of an atelectasis of the designated lobe and thereby reduction of hyperinflation and hence reduction of symptoms and increase in pulmonary function

In this study the aim is to assess:

1. If the movement of the diaphragm improves after insertion of endobronchial valves in patients with severe emphysema. 2. If there is a correlation between improvement of diaphragm function and improvement of symptoms, lung function examinations and physical ability after insertion of endobronchial valves. 3. If immediate post-procedural ultrasound evaluation of diaphragm function predicts the development of atelectasis and hence clinical outcome

Первичные конечные точки

  • Diaphragm mobility [Срок оценки: Before the procedure, 1 day after the procedure and 90 days after the procedure]
  • Diaphragm mobility [Срок оценки: Before the procedure, 1 day after the procedure and 90 days after the procedure]
  • Diaphragm Thickening [Срок оценки: Before the procedure, 1 day after the procedure and 90 days after the procedure]
Вторичные конечные точки (11)
  • Forced expiratory volume in 1 second in litres [Срок оценки: Before and 90 days after the procedure]
  • Forced expiratory volume in 1 second % of expected [Срок оценки: Before and 90 days after the procedure]
  • Forced vital capacity in litres [Срок оценки: Before and 90 days after the procedure]
  • Forced vital capacity in % of expected [Срок оценки: Before and 90 days after the procedure]
  • Total lung volume in % of expected [Срок оценки: Before and 90 days after the procedure]
  • Residual volume in % of expected [Срок оценки: Before and 90 days after the procedure]
  • diffusion capacity in % of expected [Срок оценки: Before and 90 days after the procedure]
  • 6 Minute walking test [Срок оценки: Before and 90 days after the procedure]
  • Rate of atelectasis on Lung X-ray [Срок оценки: Before, one day and 90 days after the procedure]
  • Medical Research Council (MRC) Dyspnoea Scale [Срок оценки: Before, one day and 90 days after the procedure]
  • COPD Assessment Test (CAT) Score [Срок оценки: Before, one day and 90 days after the procedure]

Критерии участия

Критерии включения

  • Patients selected to receive treatment with endobronchial valves
  • Signed informed consent

Критерии исключения

  • Neuromuscular disease interfering with diaphragm function
  • Pleural effusion at time of preoperative or 90-days postoperative ultrasound

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Дания · 1 центр
  • Aarhus University Hospital — Aarhus

Идентификаторы

NCT: NCT06163131 · KH02

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗